GlassScriptPhysician profile
Camille Farris
NPI 1629654793
$2,645.72
in general payments reported to CMS, 2019-2025
29 companies · $59.13 in 2025
The $59.13 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,478 · 2022: $711 · 2023: $250 · 2024: $148 · 2025: $59.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.16 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $252.79 | 2021 | |
| Lilly USA, LLC | $249.01 | 2021-2022 | |
| Gilead Sciences, INC. | $245.14 | 2023-2024 | Epclusa |
| Abbvie INC. | $233.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $227.25 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $162.70 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.75 | 2021-2022 | |
| Amgen INC. | $124.06 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.82 | 2022 | |
| Xeris Pharmaceuticals, INC. | $110.78 | 2021-2022 | |
| Mannkind Corporation | $71.70 | 2021-2022 | |
| Janssen Biotech, INC. | $43.37 | 2022-2023 | Simponi Aria, Remicade, Stelara |
| Amarin Pharma, INC. | $43.03 | 2021-2022 | |
| Insulet Corporation | $42.10 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.73 | 2021-2022 | |
| Corcept Therapeutics | $23.87 | 2021 | |
| Ibsa Pharma INC. | $22.73 | 2022 | |
| Travere Therapeutics, INC. | $22.22 | 2023 | |
| Grt US Holding, INC. | $21.63 | 2022 | |
| Dexcom, INC. | $18.75 | 2021 | |
| Intercept Pharmaceuticals, INC. | $17.78 | 2023 | Ocaliva |
| Endo Pharmaceuticals INC. | $17.50 | 2023 | Xiaflex |
| Leo Pharma INC. | $16.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.23 | 2021 | |
| Tandem Diabetes Care, INC. | $14.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.71 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.06 | 2022 | |
| Medtronic, INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.